Published in Pharmacol Ther on August 10, 2010
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry (2013) 1.92
Animal models of schizophrenia. Br J Pharmacol (2011) 1.60
New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats. Neuropharmacology (2011) 1.37
NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proc Natl Acad Sci U S A (2012) 1.32
Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome. Proc Natl Acad Sci U S A (2011) 1.26
Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol (2013) 1.13
The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl) (2011) 1.09
Predictive animal models of mania: hits, misses and future directions. Br J Pharmacol (2011) 1.04
The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Br J Pharmacol (2013) 1.04
CNTRICS final animal model task selection: control of attention. Neurosci Biobehav Rev (2012) 1.02
Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits. CNS Neurosci Ther (2013) 0.98
Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol (2015) 0.97
Effects of low-dose D-serine on recognition and working memory in mice. Psychopharmacology (Berl) (2011) 0.95
Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology (2011) 0.95
Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia. Eur Neuropsychopharmacol (2013) 0.92
Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PLoS One (2013) 0.91
Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology (Berl) (2011) 0.90
The pharmacogenetics of symptom response to antipsychotic drugs. Psychiatry Investig (2012) 0.89
The application of selective reaction monitoring confirms dysregulation of glycolysis in a preclinical model of schizophrenia. BMC Res Notes (2012) 0.89
Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov (2016) 0.88
Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.86
Beyond dopamine: glutamate as a target for future antipsychotics. ISRN Pharmacol (2012) 0.86
Inhibition of parvalbumin-expressing interneurons results in complex behavioral changes. Mol Psychiatry (2015) 0.86
Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats. Psychopharmacology (Berl) (2011) 0.85
Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism. Psychopharmacology (Berl) (2010) 0.84
Effects of ketamine-induced psychopathological symptoms on continuous overt rhyme fluency. Eur Arch Psychiatry Clin Neurosci (2011) 0.84
The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology (Berl) (2012) 0.84
Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date. CNS Drugs (2015) 0.84
Effect of MK-801-induced impairment of inhibitory avoidance learning in zebrafish via inactivation of extracellular signal-regulated kinase (ERK) in telencephalon. Fish Physiol Biochem (2012) 0.83
Serotoninergic and dopaminergic modulation of cortico-striatal circuit in executive and attention deficits induced by NMDA receptor hypofunction in the 5-choice serial reaction time task. Front Neural Circuits (2014) 0.83
Drug models of schizophrenia. Ther Adv Psychopharmacol (2015) 0.82
Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia. Eur Neuropsychopharmacol (2013) 0.82
5-HT7 receptor stimulation and blockade: a therapeutic paradox about memory formation and amnesia. Front Behav Neurosci (2014) 0.82
Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model. Neuropsychopharmacology (2015) 0.82
Deficits in emotional learning and memory in an animal model of schizophrenia. Behav Brain Res (2012) 0.82
The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Curr Neuropharmacol (2014) 0.82
Local inactivation of Gpr88 in the nucleus accumbens attenuates behavioral deficits elicited by the neonatal administration of phencyclidine in rats. Mol Psychiatry (2014) 0.82
Challenges in understanding psychiatric disorders and developing therapeutics: a role for zebrafish. Dis Model Mech (2015) 0.81
A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology (Berl) (2013) 0.81
Stress-induced impairments in prefrontal-mediated behaviors and the role of the N-methyl-D-aspartate receptor. Neuroscience (2012) 0.81
Impaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia. Int J Neuropsychopharmacol (2014) 0.80
The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats. Psychopharmacology (Berl) (2013) 0.80
Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats. Psychopharmacology (Berl) (2014) 0.80
Inhibition of the tyrosine phosphatase STEP61 restores BDNF expression and reverses motor and cognitive deficits in phencyclidine-treated mice. Cell Mol Life Sci (2015) 0.80
In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia. Psychopharmacology (Berl) (2014) 0.79
Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains. Neuropsychopharmacology (2015) 0.79
Chronic nicotine attenuates phencyclidine-induced impulsivity in a mouse serial reaction time task. Behav Brain Res (2013) 0.79
The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophrenia. Future Neurol (2015) 0.79
Electrophysiological and behavioral responses to ketamine in mice with reduced Akt1 expression. Psychopharmacology (Berl) (2013) 0.79
A combined metabonomic and proteomic approach identifies frontal cortex changes in a chronic phencyclidine rat model in relation to human schizophrenia brain pathology. Neuropsychopharmacology (2013) 0.79
Translational Aspects of the Novel Object Recognition Task in Rats Abstinent Following Sub-Chronic Treatment with Phencyclidine (PCP): Effects of Modafinil and Relevance to Cognitive Deficits in Schizophrenia. Front Psychiatry (2010) 0.79
Assessing social engagement in heterogeneous groups of zebrafish: a new paradigm for autism-like behavioral responses. PLoS One (2013) 0.78
Positive allosteric modulation of GABAB receptors ameliorates sensorimotor gating in rodent models. CNS Neurosci Ther (2014) 0.78
Deletion of the NMDA-NR1 receptor subunit gene in the mouse nucleus accumbens attenuates apomorphine-induced dopamine D1 receptor trafficking and acoustic startle behavior. Synapse (2013) 0.78
Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. Neuropsychopharmacology (2012) 0.78
A cell-based functional assay using a green fluorescent protein-based calcium indicator dCys-GCaMP. Assay Drug Dev Technol (2014) 0.78
Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia. BMC Neurosci (2015) 0.77
Effects of antipsychotics on dentate gyrus stem cell proliferation and survival in animal models: a critical update. Neural Plast (2012) 0.77
Expression analysis in a rat psychosis model identifies novel candidate genes validated in a large case-control sample of schizophrenia. Transl Psychiatry (2015) 0.77
Intra-accumbens injection of a dopamine aptamer abates MK-801-induced cognitive dysfunction in a model of schizophrenia. PLoS One (2011) 0.77
Disruption of medial prefrontal synchrony in the subchronic phencyclidine model of schizophrenia in rats. Neuroscience (2014) 0.76
Increasing endocannabinoid levels in the ventral pallidum restore aberrant dopamine neuron activity in the subchronic PCP rodent model of schizophrenia. Int J Neuropsychopharmacol (2014) 0.76
The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects. Br J Pharmacol (2015) 0.76
Altered neuronal excitability underlies impaired hippocampal function in an animal model of psychosis. Front Behav Neurosci (2015) 0.76
Delayed emergence of behavioral and electrophysiological effects following juvenile ketamine exposure in mice. Transl Psychiatry (2015) 0.76
In vivo neurometabolic profiling to characterize the effects of social isolation and ketamine-induced NMDA antagonism: a rodent study at 7.0 T. Schizophr Bull (2013) 0.76
Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission. Psychopharmacology (Berl) (2011) 0.76
Chronic ketamine produces altered distribution of parvalbumin-positive cells in the hippocampus of adult rats. Neurosci Lett (2013) 0.76
A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia. Cell Tissue Res (2013) 0.76
Severe cross-modal object recognition deficits in rats treated sub-chronically with NMDA receptor antagonists are reversed by systemic nicotine: implications for abnormal multisensory integration in schizophrenia. Neuropsychopharmacology (2012) 0.76
Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus. Neuropharmacology (2015) 0.76
PCP-based mice models of schizophrenia: differential behavioral, neurochemical and cellular effects of acute and subchronic treatments. Psychopharmacology (Berl) (2015) 0.76
A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia. BMC Psychiatry (2016) 0.76
Antioxidant Treatment with N-acetyl Cysteine Prevents the Development of Cognitive and Social Behavioral Deficits that Result from Perinatal Ketamine Treatment. Front Behav Neurosci (2017) 0.76
The nitric oxide donor sodium nitroprusside attenuates recognition memory deficits and social withdrawal produced by the NMDA receptor antagonist ketamine and induces anxiolytic-like behaviour in rats. Psychopharmacology (Berl) (2015) 0.76
Effects of the phencyclidine model of schizophrenia and nicotine on total and categorized ultrasonic vocalizations in rats. Behav Pharmacol (2016) 0.75
Examining the reinforcement-enhancement effects of phencyclidine and its interactions with nicotine on lever-pressing for a visual stimulus. Behav Brain Res (2015) 0.75
Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine. Transl Psychiatry (2016) 0.75
The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia. Psychopharmacology (Berl) (2015) 0.75
THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia. J Psychopharmacol (2015) 0.75
Comparing the effects of subchronic phencyclidine and medial prefrontal cortex dysfunction on cognitive tests relevant to schizophrenia. Psychopharmacology (Berl) (2015) 0.75
Inducible Nitric Oxide Inhibitors Block NMDA Antagonist-Stimulated Motoric Behaviors and Medial Prefrontal Cortical Glutamate Efflux. Front Pharmacol (2015) 0.75
Modulation of neuronal microcircuit activities within the medial prefrontal cortex by mGluR5 positive allosteric modulator. J Psychopharmacol (2014) 0.75
Regional brain dysregulation of Ca(2+)-handling systems in ketamine-induced rat model of experimental psychosis. Cell Tissue Res (2015) 0.75
Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys. Psychopharmacology (Berl) (2015) 0.75
Impaired hippocampal-dependent memory and reduced parvalbumin-positive interneurons in a ketamine mouse model of schizophrenia. Schizophr Res (2016) 0.75
Dopamine D1 receptor activation improves PCP-induced performance disruption in the 5C-CPT by reducing inappropriate responding. Behav Brain Res (2015) 0.75
Preclinical non-human models to combat dementia. Ann Neurosci (2013) 0.75
Negative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion. J Psychopharmacol (2015) 0.75
An Algorithm to Identify Target-Selective Ligands - A Case Study of 5-HT7/5-HT1A Receptor Selectivity. PLoS One (2016) 0.75
Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia. Transl Psychiatry (2017) 0.75
Opposing effects of glutamatergic and GABAergic pharmacological manipulations on a visual perception task with relevance to schizophrenia. Psychopharmacology (Berl) (2015) 0.75
Serotonin (5-HT)1A receptor agonism and 5-HT7 receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice. Psychopharmacology (Berl) (2015) 0.75
Postnatal Administration of Dizocilpine Inhibits Neuronal Excitability in PFC and Induces Social Deficits Detected by MiceProfiler. Mol Neurobiol (2016) 0.75
Effect of clozapine on ketamine-induced deficits in attentional set shift task in mice. Psychopharmacology (Berl) (2017) 0.75
Regulation of hemolysin expression and virulence of Staphylococcus aureus by a serine/threonine kinase and phosphatase. PLoS One (2010) 1.34
A hemolytic pigment of Group B Streptococcus allows bacterial penetration of human placenta. J Exp Med (2013) 1.31
Genetic locus encoding functions involved in biosynthesis and outer membrane localization of xanthomonadin in Xanthomonas oryzae pv. oryzae. J Bacteriol (2002) 1.21
Regulation of CovR expression in Group B Streptococcus impacts blood-brain barrier penetration. Mol Microbiol (2010) 1.18
Threonine phosphorylation prevents promoter DNA binding of the Group B Streptococcus response regulator CovR. Mol Microbiol (2009) 1.13
Structure of Streptococcus agalactiae serine/threonine phosphatase. The subdomain conformation is coupled to the binding of a third metal ion. FEBS J (2007) 1.09
MtaR, a regulator of methionine transport, is critical for survival of group B streptococcus in vivo. J Bacteriol (2003) 1.09
Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci Lett (2002) 0.97
Serine/threonine phosphatase Stp1 mediates post-transcriptional regulation of hemolysin, autolysis, and virulence of group B Streptococcus. J Biol Chem (2011) 0.96
Group B Streptococcus CovR regulation modulates host immune signalling pathways to promote vaginal colonization. Cell Microbiol (2013) 0.95
Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology (Berl) (2009) 0.94
Identification of serine/threonine kinase substrates in the human pathogen group B streptococcus. J Proteome Res (2009) 0.94
Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am J Pathol (2013) 0.93
Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol (2013) 0.91
PNU-120596, a positive allosteric modulator of α7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats. J Psychopharmacol (2011) 0.90
The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. Curr Pharm Des (2014) 0.89
Susceptibility-weighted imaging in the experimental autoimmune encephalomyelitis model of multiple sclerosis indicates elevated deoxyhemoglobin, iron deposition and demyelination. Mult Scler (2012) 0.89
Neonatal lipopolysaccharide induces pathological changes in parvalbumin immunoreactivity in the hippocampus of the rat. Behav Brain Res (2009) 0.89
Effect of subchronic phencyclidine administration on sucrose preference and hippocampal parvalbumin immunoreactivity in the rat. Neurosci Lett (2010) 0.88
Regulation of prokaryotic gene expression by eukaryotic-like enzymes. Curr Opin Microbiol (2012) 0.87
Spatial and object working memory impairments in schizophrenia patients: a Bayesian item-response theory analysis. J Abnorm Psychol (2002) 0.86
Iron quantification of microbleeds in postmortem brain. Magn Reson Med (2010) 0.84
Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat. Behav Brain Res (2009) 0.84
Two paediatric cases of skin and soft-tissue infections due to clindamycin-resistant Staphylococcus aureus carrying a plasmid-encoded vga(A) allelic variant for a putative efflux pump. Int J Antimicrob Agents (2011) 0.84
Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism. Psychopharmacology (Berl) (2010) 0.84
Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism. J Neurochem (2013) 0.83
D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia. Eur Neuropsychopharmacol (2009) 0.83
Structure of the Streptococcus agalactiae family II inorganic pyrophosphatase at 2.80 A resolution. Acta Crystallogr D Biol Crystallogr (2007) 0.82
Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats. Behav Brain Res (2009) 0.82
Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat. Behav Brain Res (2008) 0.82
Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol (2010) 0.82
Phencyclidine (PCP)-induced disruption in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brain. J Mol Neurosci (2010) 0.82
Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: implications for therapy of cognitive dysfunction in schizophrenia. Eur Neuropsychopharmacol (2010) 0.82
Vaccination with a UV-irradiated genetically attenuated mutant of Staphylococcus aureus provides protection against subsequent systemic infection. J Infect Dis (2012) 0.81
PD168077, a D(4) receptor agonist, reverses object recognition deficits in rats: potential role for D(4) receptor mechanisms in improving cognitive dysfunction in schizophrenia. J Psychopharmacol (2010) 0.81
Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat. Behav Brain Res (2010) 0.80
Crystallization and preliminary crystallographic analysis of two Streptococcus agalactiae proteins: the family II inorganic pyrophosphatase and the serine/threonine phosphatase. Acta Crystallogr Sect F Struct Biol Cryst Commun (2006) 0.80
Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacology (Berl) (2009) 0.79
Comparison of T2 and T2*-weighted MR molecular imaging of a mouse model of glioma. BMC Med Imaging (2013) 0.79
Aspects of eukaryotic-like signaling in Gram-positive cocci: a focus on virulence. Future Microbiol (2011) 0.79
Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia. J Mol Neurosci (2009) 0.79
Clorgyline-mediated reversal of neurological deficits in a Complexin 2 knockout mouse. Hum Mol Genet (2010) 0.78
Structure and substrate recognition of the Staphylococcus aureus protein tyrosine phosphatase PtpA. J Mol Biol (2011) 0.77
First episode psychosis patients show impaired cognitive function--a study of a South Asian population in the UK. J Psychopharmacol (2013) 0.77
In vivo iron quantification in collagenase-induced microbleeds in rat brain. Magn Reson Med (2011) 0.77
Sub-chronic phencyclidine administration increases brain-derived neurotrophic factor in the RAT hippocampus. Schizophr Res (2007) 0.76
Radiofrequency catheter ablation in a patient with giant left atrium and permanent atrial fibrillation: maintenance of sinus rhythm at 1 year. Indian Heart J (2009) 0.75